Although roughly four in 10 patients with inflammatory bowel disease who receive anti–tumor necrosis factor therapies ultimately lose response to the drugs and require dose augmentation, loss of response is significantly less common among infliximab users receiving concomitant immunomodulators, a new study has found.
The benefits of combination therapy were limited to patients receiving infliximab, and not their counterparts receiving adalimumab (Humira, AbbVie), according to the